Business, energy, technology, markets and global industry news from Business News Today

mycosis fungoides

PharmaDeviceNews mycosis fungoides
Representative image: Laboratory analysis of T-cell lymphoma samples as Corvus Pharmaceuticals reports durable soquelitinib responses in final Phase 1/1b data, supporting its ongoing pivotal Phase 3 peripheral T-cell lymphoma trial.
Pharma & Biotech

Kyowa Kirin Poteligeo MINT study shows 62.4% response in cutaneous T-cell lymphoma

Final results from Germany's 109-patient MINT study show a 62.4% best overall response rate and median time to next treatment of 14.9 months with Poteligeo. The findings support its established role in cutaneous T-cell lymphoma while highlighting meaningful toxicity, concurrent treatment and observational-study limitations.

Read More
Innate Pharma’s lacutamab partnership with Sobi could unlock the TELLOMAK-3 Phase 3 trial and a potential accelerated approval pathway in T-cell lymphoma, with the licensing agreement carrying up to $580 million in potential value. Representative image.
Pharma & Biotech

What Sobi’s lacutamab licensing deal means for Innate Pharma and TELLOMAK-3

Innate Pharma’s Sobi deal brings $75m upfront and could unlock TELLOMAK-3, accelerated approval and global commercialization of lacutamab.

Read More